Unknown PHASE2 INTERVENTIONAL 2-arm NCT05019794

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations (FGFR)

A Phase IIa of Infigratinib in Subjects With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma With FGFR2 Amplification or Other Advanced Solid Tumors With Other FGFR Alterations

Sponsor: LianBio LLC

Conditions Gastric Cancer Gastroesophageal Junction Adenocarcinoma Solid Tumor

Interventions Infigratinib

Updated 4 times since 2021 Last updated: Jun 22, 2022 Started: May 13, 2020 Primary completion: Dec 30, 2022 Completion: Dec 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05019794, this PHASE2 trial focuses on Gastric Cancer and Gastroesophageal Junction Adenocarcinoma and remains ongoing. Sponsored by LianBio LLC, it has been updated 4 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Sep 2021 — Jul 2022 [monthly]

Recruiting PHASE2

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LianBio LLC

Data source: LianBio LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baoding, China , Beijing, China , Changzhou, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Henan, China , Nanjing, China , Shanghai, China and 3 more locations